caa a22 4500 465790100 CHVBK 20180323112021.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00177262 doi (NATIONALLICENCE)springer-10.1007/BF00177262 Pirarubicin (4′-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer [Elektronische Daten] A clinical phase II study [Werner Scheithauer, Helmut Samonigg, Dieter Depisch, Johannes Schüller, Hubert Hausmaninger, Julius Wiegele, Christoph Zielinsky, Heinz Stöger, Karin Haider, Peter Preis, Werner Seidl, Berthold Greifenberg, Heinz Ludwig] Summary: In a phase II study, 77 patients with metastatic breast cancer were treated with pirarubicin, 70 mg/m2 iv every 3 weeks. Most of them had received prior hormonal (n = 39) and/or chemotherapeutic drug treatment for advanced disease, including anthracycline-containing regimens in 17. After a median of 5.5 treatment cycles (range 1-14), objective tumor response was seen in 22/71 (31%) evaluable patients (4CR, 18 PR). Stable disease occurred in 34 (48%) patients, whereas the tumor progressed in 15 (21%). Significant hematologic toxicity (WHO grade III-IV) requiring interval and/or dose adjustments was observed in 41 (58%) patients. Other treatment-related side effects were generally mild, and included alopecia in 52 (73%), nausea and/or emesis in 50 (70%), and stomatitis and diarrhea in 3 patients each. There was no treatment-related death, nor was there any evidence of cardiac toxicity thus far. In summary, the early results of this trial suggest that pirarubicin is an active and rather well tolerated drug in pretreated patients with advanced breast cancer. Kluwer Academic Publishers, 1990 pirarubicin nationallicence anthracycline nationallicence breast cancer nationallicence phase II trial nationallicence Scheithauer Werner Department of Internal Medicine II, University of Vienna, Austria aut Samonigg Helmut Department of Medicine, University of Graz, FRG aut Depisch Dieter Department of Surgery, General Hospital Wr. Neustadt, FRG aut Schüller Johannes Department of Medicine I, Hospital Rudolfsstiftung Vienna, Austria aut Hausmaninger Hubert Department of Medicine, General Hospital Salzburg, FRG aut Wiegele Julius Department of Surgery I, University of Innsbruck, FRG aut Zielinsky Christoph Department of Internal Medicine II, University of Vienna, Austria aut Stöger Heinz Department of Medicine, University of Graz, FRG aut Haider Karin Department of Surgery, General Hospital Wr. Neustadt, FRG aut Preis Peter Department of Internal Medicine II, University of Vienna, Austria aut Seidl Werner Department of Surgery, General Hospital Wr. Neustadt, FRG aut Greifenberg Berthold Behring Werke, Marburg, FRG aut Ludwig Heinz Department of Internal Medicine II, University of Vienna, Austria aut Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 207-210 0167-6997 8:2<207 1990 8 10637 https://doi.org/10.1007/BF00177262 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177262 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Scheithauer Werner Department of Internal Medicine II, University of Vienna, Austria aut NATIONALLICENCE 700 1- Samonigg Helmut Department of Medicine, University of Graz, FRG aut NATIONALLICENCE 700 1- Depisch Dieter Department of Surgery, General Hospital Wr. Neustadt, FRG aut NATIONALLICENCE 700 1- Schüller Johannes Department of Medicine I, Hospital Rudolfsstiftung Vienna, Austria aut NATIONALLICENCE 700 1- Hausmaninger Hubert Department of Medicine, General Hospital Salzburg, FRG aut NATIONALLICENCE 700 1- Wiegele Julius Department of Surgery I, University of Innsbruck, FRG aut NATIONALLICENCE 700 1- Zielinsky Christoph Department of Internal Medicine II, University of Vienna, Austria aut NATIONALLICENCE 700 1- Stöger Heinz Department of Medicine, University of Graz, FRG aut NATIONALLICENCE 700 1- Haider Karin Department of Surgery, General Hospital Wr. Neustadt, FRG aut NATIONALLICENCE 700 1- Preis Peter Department of Internal Medicine II, University of Vienna, Austria aut NATIONALLICENCE 700 1- Seidl Werner Department of Surgery, General Hospital Wr. Neustadt, FRG aut NATIONALLICENCE 700 1- Greifenberg Berthold Behring Werke, Marburg, FRG aut NATIONALLICENCE 700 1- Ludwig Heinz Department of Internal Medicine II, University of Vienna, Austria aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 207-210 0167-6997 8:2<207 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer